Charles Mild, MD
Interventional Cardiology · Harlingen, TXNPI 1396735999
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $3,363 of the $4,701 with a category attached, or 71.5%. 10 manufacturers reported payments, led by Merck at 43.6% of the total. Reporting peaked in 2024 at $2,296 and has fallen 89.7% since, to $236 in 2025. That places this record below the midpoint for interventional cardiology clinicians in TX, where the typical reported total is $9,094.
Across 35 payments — averaging $134.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2K
- Silk Road Medical, Inc.$2K
- Abbott$385
- Medtronic$269
- Abiomed$96
- E.r. Squibb & Sons, L.L.C.$80
- plus $68 from 4 others
Across 3 payments — averaging $143.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$431
What the payments were for
- Travel & lodging$3,36372%
- Food & beverage$1,33828%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 9 | $2,051 |
| Silk Road Medical, Inc. | 6 | $1,753 |
| Abbott | 8 | $385 |
| Medtronic(2 entities) | 3 | $269 |
| Abiomed | 1 | $96 |
| E.r. Squibb & Sons, L.L.C. | 4 | $80 |
| Philips North America LLC | 1 | $21 |
| Teleflex LLC | 1 | $19 |
| Bard Peripheral Vascular, Inc. | 1 | $16 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,701 in reported general payments places this provider in the 25th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 66 | $83,092 |
| XareltoRivaroxaban | 11 | $13,645 |
| Metoprolol Succinate | 120 | $1,803 |
| Ranolazine ErRanolazine | 11 | $852 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 58 | $788 |
| Losartan Potassium | 83 | $669 |
| ClopidogrelClopidogrel Bisulfate | 66 | $614 |
| Digoxin | 17 | $534 |
| Valsartan | 20 | $454 |
| Lisinopril | 53 | $420 |
| Carvedilol | 47 | $387 |
| Ezetimibe | 20 | $355 |
| Rosuvastatin Calcium | 24 | $336 |
| Atorvastatin Calcium | 39 | $323 |
| Cilostazol | 12 | $310 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Harlingen
- Juan GranadaHouston$4.1M
- Vamsi KrishnaKyle$2M
- Jeffrey CarrTyler$1.9M
- John IsaacHouston$1.8M
- Robert ChiltonSan Antonio$1.3M
- Sameh SayfoPlano$1M
- Srinivasa PotluriPlano$781K
- Karim Al-AziziPlano$734K
- Robert StolerDallas$587K
- Peter MonteleoneKyle$461K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.